An Open-Label Exploratory Clinical Trial Evaluating the Effects of GLS (Coptidis Rhizoma-Evodiae Fructus 2 : 1) on Fibroblast Growth Factor 21 in Patients with Nonalcoholic Fatty Liver Disease

Table 5

All adverse events during treatment (n, %).

Variable	GLS (n = 59)	PPC (n = 60)	χ^2	value
Hypodynamia	0 (0)	1 (1.7)	0.000	1.000
Anorexia	1 (1.7)	3 (5)	0.242	0.623
Irritability	0 (0)	1 (1.7)	0.000	1.000
Diarrhea	1 (1.7)	1 (1.7)	0.000	1.000
Gastric distension	2 (3.4)	1 (1.7)	0.000	1.000